Results 191 to 200 of about 11,151,075 (302)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

List of Articles

, 2016
Articles, List of
core  

Condition-Specific Protocols Used in the Emergency Department Observation Unit: A Scoping Review. [PDF]

J Am Coll Emerg Physicians Open
Samadian KD, Luo AD, Pollock M, Chen H, Baugh JJ, Berdahl CT, Meeker MA, Meguerdichian DA, Baugh CW.   +8 more
europepmc   +1 more source

Australian Podiatry Research in Gerontology: A Bibliometric Analysis. [PDF]

J Foot Ankle Res
Menz HB, Nor Azhar A, Bergin SM, Tehan PE, Carroll MR.   +4 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Perspectives of Femoroacetabular Impingement Syndrome: A Bibliometric Analysis. [PDF]

Hip Pelvis
Puyol AD, Ganderton C, King M, Tirosh O.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Modèle: les grands articles d'Universalis

, 2015
Grands Articles, Les
core  

A Scoping Review of the Conceptualization, Operationalization, and Institutional Recognition of the Scholarship of Teaching and Learning in Health Professions Education: Using Institutional Logics to Understand Inconsistencies. [PDF]

Perspect Med Educ
Varpio L, Jones F, Lege-Matsuura J, Schultz K, Amiel J, Dunleavy K, Jensen GM, Jeffries PR, Ellaway R.   +8 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source